Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Trametinib

dee54768-acec-5092-b1c9-ca2027651a9e · FDA Approved · targets MEK1, MEK2

Trametinib

MeasuredReference

Trametinib targets MAP2K1, MAP2K2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

MAP2K1MAP2K2

Top hallmarks

  • tumor promoting inflammation678
  • proliferation628
  • evading apoptosis619

Top pathways disrupted

  • pi3k akt mtor signaling1.3k
  • apical junction1.2k
  • apoptosis1.1k

Resistance landscape — Trametinib

MeasuredReference

1 known oncogenic variants exist on Trametinib's top targets — see detail for inhibition impact.

Open in new tab